Elsevier

Contraception

Volume 56, Issue 3, September 1997, Pages 141-146
Contraception

Original research article
First-time use of newer oral contraceptives and the risk of venous thromboembolism

https://doi.org/10.1016/S0010-7824(97)00119-4Get rights and content

Abstract

Recent epidemiologic studies reported that the risk of venous thromboembolism (VTE) was higher with the use of the newer third generation oral contraceptives than with second generation agents. Although the overall findings of these studies are similar, the results, as they relate to patterns and duration of oral contraceptive use particularly among first-time users, are inconsistent.

We reanalyzed data from the Transnational case-control study to assess the risk of VTE associated with first-time use of oral contraceptives as a function of its duration of use. Over the period 1993 to 1995, 471 cases of venous thromboembolism were identified in Germany and the United Kingdom. For each case, up to four controls were obtained, for a total of 1772 controls. Data on oral contraceptive use and confounding variables, including data on sociodemographic, lifestyle, medical history, and family history of disease, were obtained by interview. Data analysis was based on the 105 cases and 422 controls who were first-time users of second or third generation agents, or never users of oral contraception. Rate ratios, adjusted for confounders and approximated by odds ratios, were estimated as a continuous function of duration of oral contraceptive use by logistic regression and quadratic spline models.

We found, for first-time users, that the adjusted rate tatio of VTE as a function of the duration of oral contraceptive use is essentially identical for second and third generation pills relative to never users. This rate ratio increases to around 10 in the first year of use and decreases to around two after 2 years of use, remaining at this risk level thereafter for both second and third generation agents.

We conclude that second and third generation agents are associated with identical risks of venous thromboembolism when they are prescribed to women who are using oral contraceptives for the first time ever.

References (22)

  • WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception

    Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study

  • Cited by (187)

    • Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials

      2022, Contraception
      Citation Excerpt :

      The overall estimated annual VTE incidence rate across the full E4/DRSP clinical program (pooled phase 2 and 3 trials) is 3.66/10,000 woman-years [31]. The risk of VTE is considered highest in the first 12 months of using a new COC [32], with multiple studies reporting a small increased risk in new users compared to switchers [32–34], perhaps because switchers have already demonstrated a lower risk for VTE [34]. A similar increased risk has also been observed in those re-starting a COC after an absence [35].

    • Antiandrogens and Androgen Inhibitors

      2020, Comprehensive Dermatologic Drug Therapy, Fourth Edition
    • Women, thrombosis, and cancer

      2019, Thrombosis Research
    View all citing articles on Scopus

    Funded in part by grants from Organon, Schering AG, and the Fonds de la Recherche en Santé du Québec (FRSQ). Samy Suissa is a Senior Research Scholar of the FRSQ. Lucie Blais is the recipient of a doctoral scholarship from the National Health and Development Program of Canada (NHRDP). The McGill Pharmacoepidemiology Research Unit is funded by the FRSQ.

    View full text